Accuray (ARAY)
(Delayed Data from NSDQ)
$2.03 USD
+0.11 (5.73%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.97 -0.06 (-2.96%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.03 USD
+0.11 (5.73%)
Updated Nov 6, 2024 04:00 PM ET
After-Market: $1.97 -0.06 (-2.96%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Zacks News
Fresenius Medical (FMS) Q4 Earnings Beat Estimates, Up Y/Y
by Zacks Equity Research
Fresenius Medical's (FMS) fourth-quarter earnings benefit from strong segmental performance and solid 2020 EPS outlook.
Integer Holdings (ITGR) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Integer Holdings' (ITGR) fourth-quarter earnings benefit from higher revenues and strong segmental performance.
Masimo (MASI) Q4 Earnings Beat Estimates, View Impressive
by Zacks Equity Research
Masimo (MASI) sees expansion in gross and operating margin in Q4.
Syneos Health (SYNH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
We are upbeat about the strong year-over-year revenue growth in the Clinical Solutions segment of Syneos Health (SYNH) in Q4.
Henry Schein (HSIC) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Henry Schein (HSIC) registers solid performance by each of its key operating businesses in Q4.
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Smith Micro Software, Accuray, Vista Outdoor, Synaptics and CareDx
Amedisys (AMED) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Amedisys' (AMED) fourth-quarter earnings benefit from solid year-over-year growth in Medicare and non-Medicare revenues within Home Health.
Ecolab (ECL) Earnings and Revenues Miss Estimates in Q4
by Zacks Equity Research
Strength in the Global Industrial arm drives Ecolab's (ECL) Q4 results.
Medtronic (MDT) Q3 Earnings Top Estimates, Revenues Miss
by Zacks Equity Research
Medtronic (MDT) demonstrates better-than-expected Q3 performances at CER, backed by growth in all major business segments and geographies.
Trump Mulling Tax Cuts to Incentivize Stock Buying? 6 Picks
by Nalak Das
President Trump's tenure has seen Wall Street perform exceptionally well so far. In fact, Trump often cites Wall Street's bull run as a reflection of his good governance.
Change Healthcare (CHNG) Q3 Earnings Top Estimates, Down Y/Y
by Zacks Equity Research
Change Healthcare's (CHNG) third-quarter fiscal earnings benefit from solid performance across the segments - Software and Analytics and Network Solutions. However, decline in revenues remains a woe.
DexCom (DXCM) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter earnings benefit from higher revenues and solid performing Sensor and Transmitter segments.
Bio-Rad (BIO) Q4 Earnings & Revenues Fall Short of Estimates
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2019 results reflect strong segmental performances.
AMN Healthcare (AMN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
AMN Healthcare's (AMN) Q4 results gain from core Nurse and Allied Solutions units.
LabCorp's (LH) Q4 Earnings Beat Estimates, Margins Rise
by Zacks Equity Research
LabCorp (LH) registered year-over-year growth in operating segments in Q4.
Ares Management (ARES) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ares Management (ARES) delivered earnings and revenue surprises of 34.00% and 14.03%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Accuray, MagnaChip Semiconductor, Rite Aid, Vericel and RGC Resources
CVS Health (CVS) Q4 Earnings Top Estimates, Margins Improve
by Zacks Equity Research
CVS Health (CVS) registers strong growth in Pharmacy Services, benefiting from the upside in specialty services.
Exact Sciences (EXAS) Q4 Earnings and Revenues Rise Y/Y
by Zacks Equity Research
Exact Sciences' (EXAS) fourth-quarter 2019 results reflect strong segmental performances.
Virus or No Virus, Investing Case in US Stocks Looks Solid!
by Tirthankar Chakraborty
U.S. stocks are heavily exposed to the domestic economy where data continues to improve. And even if skeptics worry about the virus outbreak, developed markets are more stable than emerging markets during chaotic times.
Radware (RDWR) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Radware (RDWR) delivered earnings and revenue surprises of -4.17% and -0.22%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in the United States in Q4.
STERIS (STE) Surpasses Q3 Earnings Estimates, Ups FY20 View
by Zacks Equity Research
STERIS' (STE) third-quarter fiscal 2020 results reflect strong segmental performances.
Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.